
Abritiga 250mg Tablet
Salt Composition: Abiraterone Acetate
Expiry Date: 01/2028
Inclusive of all taxes
120 tablet(s) in a bottle
About The Product
PROSTATE CANCER
Description
Abritiga 250mg tablet is widely used in the treatment of prostate gland in men, prescribed by healthcare professional. Its generic name is Abiraterone Acetate, taken in the form of 250mg tablet.
The medication is used in the combination of chemotherapy and also given with steroid medications to lower the chances of side effects. The drug works by inhibiting the production of certain hormones that promote the growth of prostate cancer.
Strict medical supervision is highly recommended while taking the medication.
Users and indications
Prostate gland cancer
Common side effects
Every medication shows several side effects, so patients should monitor their health and consult the doctor if any of these persist:
● Fatigue
● Vomiting
● Cough
● High blood pressure
● Headache
● Hot flashes
● Joint swelling
● Urinary tract infection
● Anemia
Dosage and administration
- Abritiga 250mg tablet is taken orally twice a day with or without food to enhance the effectiveness of the treatment.
- Do not administer yourself; it should only be taken under the supervision of a healthcare professional as the doctor suggest the right dose according to patient health and response to the treatment.
Mechanism of action
Abiritiga 250mg tablet blocks the enzyme named CYP17 which is involved in the production of androgen hormones such as testosterone. By reducing testosterone levels, it helps stop the growth of certain cancer cells in the body.
The tablet also limits the availability of nutrients that cancer cells need to grow and develop. Consultation is needed at the time of treatment.
Safety advice
FAQs
Abritiga 250mg tablet duration is depending on patient medical history and response to the treatment, consult the doctor about dosage and duration to ensure safety and effectiveness.
Reference
• Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018).
Abiraterone acetate in the treatment of prostate cancer. Biomedicine & Pharmacotherapy, 101, 211-218. • Logothetis, C.
J., Efstathiou, E., Manuguid, F., & Kirkpatrick, P. (2011).
Abiraterone acetate. Nature Reviews Drug Discovery, 10(8), 573. • Scott, L.
J. (2017).
Abiraterone acetate: a review in metastatic castration-resistant prostrate cancer. Drugs, 77(14), 1565-1576. • Attard, G., Reid, A.
H., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., ... & de Bono, J.
S. (2009).
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of clinical oncology, 27(23), 3742-3748.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
